|

Relugolix Clinical Trials

10 actively recruiting trials across 9 locations

▲ +1 trial since May 2026

Also known as: N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea, Orgovyx, Relumina, TAK 385, TAK-385 +3 more

Pipeline

Phase 1: 1Phase 2: 6Phase 3: 3

Top Sponsors

  • Mayo Clinic2
  • Qilu Pharmaceutical Co., Ltd.1
  • Ohio State University Comprehensive Cancer Center1
  • Northwestern University1
  • Emory University1

Indications

  • Cancer10
  • Prostate Adenocarcinoma4
  • Heart Disease2
  • Stage IIC Prostate Cancer AJCC v82
  • Biochemically Recurrent Prostate Carcinoma2

Other1 trial

Anchorage, Alaska1 trial

Phoenix, Arizona1 trial

Scottsdale, Arizona1 trial

Miami, Florida1 trial

Orlando, Florida1 trial

Atlanta, Georgia1 trial

Chicago, Illinois1 trial

Boston, Massachusetts1 trial

Columbus, Ohio1 trial

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.